{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-040152","form_type":"8-K","ticker":"RNAZ","cik":"0001829635","company_name":"Transcode Therapeutics, Inc.","filed_at":"2023-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.886791+00:00","generated_at":"2026-06-17T08:19:16.884572+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"TransCode Therapeutics reports 2022 operating loss of $17.9M; cash runway into Q2 2023","bullets":["Cash at Dec 31, 2022: $5.0M, down from $20.8M at Dec 31, 2021.","Operating loss of $17.9M in 2022 vs $6.8M in 2021; R&D expense $10.5M (up from $2.8M).","Cash of $5.0M plus $1.3M from Feb 2023 offering and $871k SBIR expected to fund into but not through Q2 2023.","FDA authorized Phase 0 FIH trial for lead candidate TTX-MC138 in advanced solid tumors.","Strategic alliance with MD Anderson and Orphan Drug Designation for TTX-siPDL1 in pancreatic cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-040152","json":"https://secwatch.observer/filing/0001104659-23-040152.json","markdown":"https://secwatch.observer/filing/0001104659-23-040152.md","text":"https://secwatch.observer/filing/0001104659-23-040152.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829635/000110465923040152/0001104659-23-040152-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829635/000110465923040152/tm2310837d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T08:19:16.884572+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ae6f19a66a0163478f3a60c3171ff92edaf5690f","claim":"Transcode Therapeutics, Inc. reported financial results for the year ended December 31, 2022.","evidence_excerpt":"TransCode Therapeutics, Inc. issued a press release announcing its financial results for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829635/000110465923040152/0001104659-23-040152-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}